Essential fatty acids

Alternative Therapies in Health and Medicine

Volumn 12, Issue 3, 2006, Pages 20-31

  Lerman, Robert H ^a  

^a MetaProteomics LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ARACHIDONIC ACID; COLCHICINE; CORN OIL; CORTISONE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOCOSAHEXAENOIC ACID; DOCOSATRIENE; ESSENTIAL FATTY ACID; FISH OIL; GAMMA LINOLENIC ACID; IBUPROFEN; ICOSANOID; ICOSAPENTAENOIC ACID; INDOMETACIN; LIPOXYGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; PROSTANOID; QUERCETIN; RESOLVIN; SOYBEAN OIL; STEROID; THROMBOXANE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTINUING EDUCATION; CORONARY ARTERY DISEASE; CROHN DISEASE; DIET THERAPY; DIETARY INTAKE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FAT INTAKE; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FISH; FOOD INTAKE; HEART INFARCTION; HUMAN; ICOSANOID METABOLISM; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; LIPID MEMBRANE; LIPID METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHOLIPID MEMBRANE; POSTGRADUATE EDUCATION; PROSTAGLANDIN SYNTHESIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; STROKE;

ASTHMA; CARDIOVASCULAR DISEASES; DIETARY FATS, UNSATURATED; FATTY ACIDS, ESSENTIAL; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATORY BOWEL DISEASES; KIDNEY DISEASES; LIPID METABOLISM; NEOPLASMS; PSORIASIS;

EID: 33646592219     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Zaloga GP, Marik P. Lipid modulation and systemic inflammation. Critical Care Clinics. 2001;17(1):201-17.
2. Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002;56:388-96.
3. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002;61:345-58.
4. Siguel EN. Essential Fatty Acids in Health and Disease. First edition. Nutrek Press, Brookline, MA, 1994:24.
5. Sharma S, Sharma SC. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems. Indian J Exp Biol. 1997;35(10):1025-31.
6. Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002;56:388-96.
7. Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J. 2004 Dec;18(15):1791-800.
8. Ibid.
9. Serhan CN. Novel omega - 3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther. 2005;105(1):7-21.
10. Ibid.
11. Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 2004;73(3-4):155-72.
12. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002;61:345-58.
13. Horrobin DF. Essential fatty acids: a review. In: Clinical Uses of Fatty Acids, edited by David F Horrobin, Eden Press, Inc, Montreal - London, pp 3-36, 1982.
14. Clarke SD. Personal communication. 2001.
15. Horrobin DF. Essential fatty acids: a review. In: Clinical Uses of Fatty Acids, edited by David F Horrobin, Eden Press, Inc, Montreal - London, pp 3-36, 1982.
16. Diaz BL, Arm JP. Phospholipase A2. Prostaglandins Leukot Essent Fatty Acids. 2003;69:87-97.
17. Lindahl M, Tagesson C. Selective inhibition of group II phospholipase A2 by quercetin. Inflammation. 1993;17(5):573-82.
18. Tapiero H, Nguyen Ba G, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother. 2002;56:215-22.
19. Tjendraputra E, Tran VH, Liu-Brennan D, et al. Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. Bioorg Chem. 2001;29(3):156-63.
20. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 2001;172(2):111-18.
21. Vane JR. The mode of action of aspirin and similar compounds. J Allergy Clin Immunol. 1976;58(6):691-712.
22. Tjendraputra E, Tran VH, Liu-Brennan D, et al. Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. Bioorg Chem. 2001;29(3):156-63.
23. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 2001;172(2):111-18.
24. Dong WG, Mei Q, Yu JP, et al. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 2003;9(6):1307-11.
25. Kundu JK, Na HK, Chun KS, et al. Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells. J Nutr. 2003;133(11 Suppl 1):3805S-10S.
26. Cheong E, Ivory K, Doleman J, et al. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis. 2004;25(10):1945-52.
27. Vane JR. The mode of action of aspirin and similar compounds. J Allergy Clin Immunol. 1976;58(6):691-712.
28. Tripp M, Babish J, Darland G, et al. Hop and modified hop extracts have potent in vitro anti-inflammatory properties. Presentation. First International Humulus Symposium August 2, 2004, Corvallis, OR.
29. Peters-Golden M, McNish RW, Davis JA, et al. Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages. Am J Physiol. 1996;271(6 Pt 1):L1004-13.
30. Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. Curr Med Chem. 2004;11(9):1113-33.
31. Prasad NS, Raghavendra R, Lokesh BR, Naidu KA. Spice phenolics inhibit human PMNL 5-lipoxygenase. Prostaglandins Leukot Essent Fatty Acids. 2004;70(6):521-28.
32. Ibid.
33. Ibid.
34. MacCarrone M, Lorenzon T, Guerrieri P, Agro AF. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999;265(1):27-34.
35. Sendl A, Elbl G, Steinke B, et al. Comparative pharmacological investigations of Allium ursinum and Allium sativum. Planta Med. 1992;58(1):1-7.
36. Safayhi H, Mack T, Sabieraj J, et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992;261(3):1143-46.
37. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021-29.
38. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96(1):272-77.
39. Krum H, Liew D, Aw J, Jaas S. Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert Rev Cardiovasc Ther. 2004;2(2):265-70.
40. Burdge G. Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr Metab Care. 2004;7(2):137-44.
41. Barham JB, et al. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr. 2000;130:1925-31.
42. Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 1985;312(19):1217-24.
43. Ibid.
44. Stoll BA, N-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J Nutr. 2002;87(3):193-98.
45. Dandona P, Aljada A, Chaudhuri A. Vascular reactivity and thiazolidinediones. Am J Med. 2003;115 Suppl 8A:81S-86S.
46. Zampelas A, Paschos G, Rallidis L, Yiannakouris N. Linoleic acid to alpha-linoienic acid ratio. From clinical trials to inflammatory markers of coronary artery disease. World Rev Nutr Diet. 2003;92:92-108.
47. Holman RT. The slow discovery of the importance of omega-3 essential fatty acids in human health. J Nutr. 1998;128:427S-33S.
48. Chilton-Lopez, Surette ME, Swan DD, Metabolism of gammalinolenic acid in human neutrophils. J Immunol. 1996;156(8):2941-47.
49. Belch JJF, Hill A. Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr. 2000;71(suppl):352S-56S.
50. Barham JB, et al. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr. 2000;130:1925-31.
51. Pischon T, Hankinson SE, Hotamisligil GS, et al. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108:155-60.
52. Hishinuma T, Nakamura H, Sawai T, et al. Analysis of urinary prostacyclin and thromboxane/prostacyclin ratio in patients with rheumatoid arthritis using gas chromatography/selected ion monitoring. Prostaglandins Leukot Essent Fatty Acids. 2001;65(2):85-90.
53. Cleland LG, James MJ, Proudman SM. The role offish oils in the treatment of rheumatoid arthritis. Drugs. 2003;63(9):845-53.
54. Ibid.
55. Ibid.
56. Adam O, Beringer C, Kless T, et al. Anti-inflammatory effects of a low arachidonic acid dirt and fish oil in patients with rheumatoid arthritis. Rheumatol Int. 2003;23:27-36.
57. Cleland LG, James MJ, Proudman SM. The role of fish oils in the treatment of rheumatoid arthritis. Drugs. 2003;63(9):845-53.
58. Hishinuma T, Nakamura H, Sawai T, et al. Analysis of urinary prostacyclin and thromboxane/prostacydin ratio in patients with rheumatoid arthritis using gas chromatography/selected ion monitoring. Prostaglandins Leukot Essent Fatty Acids. 2001;65(2):85-90.
59. Soeken KL, Miller SA, Ernst E. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2003;42(5):652-59.
60. Zurier RB, Rossetti RG, Jacobson EW, et al. Gamma-linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum. 1996;39(11):1808-17.
61. Remans PH, Sont JK, Wagenaar LW, et al. Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects. Eur J Clin Nutr. 2004;58(6):839-45.
62. Siguel EN, Lerman RH. Prevalence of essential fatty acid deficiency in patients with chronic gastrointestinal disorders. Metabolism. 1996;45(1):12-23.
63. Belluzzi A, Boschi S, Brignola C, et al. Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr. 2000;71(1):339S-42S.
64. Ibid.
65. Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001;36(9):1007-24.
66. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med. 1996;334(24):1557-60.
67. Belluzzi A. N-3 fatty acids for the treatment of inflammatory bowel diseases. Proc Nutr Soc. 2002;61(3):391-95.
68. Arslan G, Brunborg LA, Froyland L. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids. 2002;37(10):935-40.
69. Ibid.
70. Bjorkkjaer T, Brunborg LA, Arslan G, et al. Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scand J Gastroenterol. 2004;39(11):1088-94.
71. Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-blind, randomized placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther. 2002;16:1131-35.
72. Donadio JV. The emerging role of omega-3 polyunsaturated fatty acids in the management of patients with IgA nephropathy. J Ren Nutr. 2001;11(3):122-28.
73. Donadio JV, Grande JP. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol. 2004;24(3):225-43.
74. Clark WF, Parbtani A. Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. Am J Kidney Dis. 1994;23(5):644-47.
75. Hernandez D, Guerra R, Milena A, et al. Dietary fish oil does not influence a cute rejection rate and graft survival after renal transplantation: a randomized placebo-controlled study. Nephrol Dial Transplant. 2002;17(5):897-904.
76. Grekas D, Kassimatis E, Makedou A, et al. Combined treatment with low-dose pravasratin and fish oil in post-renal transplantation dyslipidemia. Nephron. 2001;88(4):329-33.
77. Schmitz PG, McCloud LK, Reikes ST, et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002;13(1):184-90.
78. Mayser P, Grimm H, Grimminger F. n-3 fatty acids in psoriasis. Br J Nutr. 2002;87(Suppl 1)577-82.
79. Carey MA, Germolec DR, Langenbach R, Zeldin DC. Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids. 2003;69(2-3):157-62.
80. Calabrese C, Triggliaio M, Marone G, Mazzarella G. Arachidonic acid metabolism in inflammatory cells of patients with bronchial asthma. Allergy. 2000;55(Suppl 61):27-30.
81. Ibid.
82. Ibid.
83. Spector SL, Surette ME. Diet and asthma: has the role of dietary lipids been overlooked in the management of asthma? Ann Allergy Asthma Immunol. 2003;90(4):371-77.
84. Schacter HM, et al. Health Effects of Omega-3 Fatty Acids on Asthma. Summary, Evidence Report/Technology Assessment No. 9.2004; AHRQ Publication No 04-E013-1.
85. Wong KW. Clinical efficacy of n-3 fatty acid supplementation in patients with asthma. J Am Diet Assoc. 2005;105(1):98-105.
86. Ziboh VA, Naguwa S, Vang K, et al. Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. Clin Dev Immunol. 2004;11(1):13-21.
87. Mihrshahi S, Peat JK, Marks GB, et al. Eighteen-month outcomes of house dust mite avoidance and dietary fatty acid modification in the Childhood Asthma Prevention Study (CAFS). J Allergy Clin Immunol. 2003;111(1):162-8.
88. Mihrshahi S, Peat JK, Webb K, et al. Effect of omega-3 fatty acid concentrations in plasma on symptoms of asthma at 18 months of age. Pediatr Allergy Immunol. 2004 Dec;15(6):517-22.
89. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis. 2004;17(1):35-44.
90. Montalescot G, Maclouf J, Drobinski G, et al. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Cell Cardiol. 1994;24(1):33-38.
91. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
92. Schror K. The effect of prostaglandins and thromboxane A2 on coronary vessel tone-mechanisms of action and therapeutic implications. Eur Heart J. 1993;14(Suppl I):34-41.
93. Daviglus ML, Stamler J, Orencia AJ. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336(15):1046-53.
94. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312(19):1205-9.
95. Ibid.
96. Rodriguez BL, Sharp DS, Abbott RD, et al. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers. Circulation. 1996;94(5):952-56.
97. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279(1):23-28.
98. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346(15):1113-18.
99. Burr ML. Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2(8666):757-61.
100. Ness AR, Hughes J, Elwood PC, et al. The long-term effect of dietary advice in men with coronary disease: follow-up of the Diet and Reinfarction trial (DART). Eur J Clin Nutr. 2002;56(6):512-18.
101. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57(2):193-200.
102. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-55.
103. Barzi F, Woodward M, Marfisi RM, et al. Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial. Eur J Clin Nutr. 2003;57(4):604-11.
104. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial in-farction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897-903.
105. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454-59.
106. Leaf A. Dietary prevention of coronary heart disease: the Lyon Diet Heart Study. Circulation. 1999;99(6):733-35.
107. Ibid.
108. Singh RB, Dubnov G, Niaz MA. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet. 2002;360(9344):1455-61.
109. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med. 2001;161(18):2185-92.
110. Nestel P, Shige H, Pomeroy S. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr. 2002;76(2):326-30.
111. Harris W. Fish oils, omega-3 polyunsaturated fatty adds, and coronary heart disease. Backgrounder (Roche Vitamins Inc.) 1997;2(1):1-8.
112. Connor SL, Connor WE. Are fish oils beneficial in the prevention and treatment of coronary artery disease? Am J Clin Nutr. 1997;66(4 Suppl):1020S-31S.
113. Ibid.
114. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998;18(5):723-31.
115. Connor SL, Connor WE. Are fish oils beneficial in the prevention and treatment of coronary artery disease? Am J Clin Nutr. 1997;66(4 Suppl):1020S-31S.
116. Howe PRC. Fish oil supplements and hypertension. ISSFAL newsletter. 1996;3(4):2-5.
117. Berry ME, Hirsch J. Does dietary linolenic acid influence blood pressure? Amer J Clin Nutr. 1986;44:336-40.
118. Harris W. Fish oils, omega-3 polyunsaturated fatty acids, and coronary heart disease. Backgrounder (Roche Vitamins Inc.) 1997;2(1):1-8.
119. Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet. 2002;360(9344):1455-61.
120. Connor SL, Connor WE. Are fish oils beneficial in the prevention and treatment of coronary artery disease? Am J Clin Nutr. 1997;66(4 Suppl):1020S-31S.
121. Christensen JH. n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate variability. Dan Med Bull. 2003 Nov;50(4):347-67.
122. de Lorgeril M, Salen P. Dietary prevention of post-angioplasty re-stenosis. From illusion and disillusion to pragmatism. Nutr Metab Cardiovasc Dis. 2003;13(6):345-48.
123. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001-2007.
124. Simopoulos AP, Robinson J. The Omega Plan: The Medically Proven Diet That Restores Your Body's Essential Nutritional Balance. Harper Collins, New York, pp 7-12, 24-36, 49-60, 1998.